Issue Date | Title | Author(s) |
2018 | Age-related features of the pathogenesis of ischemic heart disease and sensitivity of patients’ DNA to cytoprotectors | Zhernakova, N. I.; Romaschenko, O. V.; Alferov, P. K.; Snegin, E. A.; Rumbesht, V. V. |
2016 | Influence of phosphocreatine on mitochondrial activity in patients with angina pectoris | Romaschenko, O. V.; Nikolaev, S. B.; Stepchenko, A. A.; Zhernakova, N. I.; Lazareva, G. A. |
2022 | Personalized approaches to the use of the antioxidant ethoxidol in patients with coronary heart disease | Romaschenko, O. V.; Pokrovsky, M. V.; Nadezhdin, S. V.; Rumbesht, V. V.; Zhernakova, N. I.; Alferov, P. K.; Grischenko, N. D. |
2020 | Polymorphism of CYP2C9 gene in patients with stable angina pectoris and its significance in pathogenesis of the disease | Romaschenko, O. V.; Snegin, E. A.; Zhernakova, N. I.; Alferov, P. K.; Zakirova, L. R. |
2022 | The cytoprotective property of ethoxidol in patients with coronary heart disease | Romaschenko, O. V.; Pokrovsky, M. V.; Nadezhdin, S. V.; Zhernakova, N. I.; Alferov, P. K. |
2018 | The importance of the smoking factor in personalized complex pharmacotherapy of ischemic heart disease with the use of metabolic correctors | Zhernakova, N. I.; Romaschenko, O. V.; Snegin, E. A.; Rumbesht, V. V.; Alferov, P. K. |